This study demonstrates α-glucosidase inhibition and prebiotic effects in intestinal microbiota, indicating potential health benefits.
This study explored the changes in the structure and α-glucosidase inhibitory activity of a non-starch polysaccharide derived from Anemarrhena asphodeloides Bunge, AABP-1B, during digestion in vitro and its effect on host intestinal microbiota. Simulations of digestion in the upper digestive tract showed that the reducing sugar content and molecular weight of AABP-1B changed slightly, though no monosaccharides were detected. AABP-1B was resistant to degradation in the simulated upper gastrointestinal environments, retained strong α-glucosidase inhibitory activity after digestion, which may be related to the lack of structural changes. In in vitro fermentation, AABP-1B enhanced the growth of commensal microorganisms, including Bacteroides , Megasphaera , and Prevotella , while inhibiting the proliferation of pathogenic bacteria, such as Escherichia-Shigella . Fermentation of AABP-1B by gut microbes resulted in a notable increase in short-chain fatty acid contents and a decrease in pH levels. Our findings showed that AABP-1B promotes intestinal health and may serve as a prebiotic in the development of functional food.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: